Half-dose versus full-dose macrocyclic gadolinium at 3-T magnetic resonance imaging in paediatric bone and soft-tissue disease
Given the recent concerns about gadolinium-based contrast agent safety, dose reduction strategies are being investigated.
To compare half-dose and standard full-dose gadoterate meglumine at 3-tesla (T) MRI in paediatric bone and soft-tissue diseases.
Materials and methods
We prospectively enrolled 45 children (age range 2.7 months to 17.5 years, median age 8.7 years, 49 total anatomical segments) with bone and soft-tissue diseases (neoplastic, inflammatory/infectious, ischaemic and vascular) imaged at 3-T MRI. Two consecutive half-doses of gadoterate meglumine (0.05 mmol/kg body weight) were administered. Two sets of post-contrast T1-weighted images were obtained, one after the first half dose and the other after the second half dose. For qualitative analysis, three radiologists, masked to the gadolinium dose, compared the diagnostic quality of the images. For quantitative analysis, we compared signal-to-noise ratio and contrast-to-noise ratio at half and full doses.
Signal-to-noise ratio and contrast-to-noise ratio did not vary significantly between the two groups. Qualitative analysis yielded excellent image quality in both post-contrast image datasets (Cohen κ=0.8).
In paediatric bone and soft-tissue 3-T MRI, it is feasible to halve the standard dose of gadoterate meglumine without losing image quality.
Keywords3-T Children Contrast agent Contrast-to-noise ratio Dose Gadolinium Gadoterate meglumine Magnetic resonance imaging Signal-to-noise ratio
Compliance with ethical standards
Conflicts of interest
- 3.American College of Radiology Committee on Drugs and Contrast Media (2017) ACR manual on contrast media version 10.3. American College of Radiology, RestonGoogle Scholar
- 16.McDonald RJ, McDonald JS, Kallmes DF et al (2017) Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities. Radiology 27:161595Google Scholar
- 21.Tibussek D, Rademacher C, Caspers J et al (2017) Gadolinium brain deposition after macrocyclic gadolinium administration: a pediatric case-control study. Radiology 21:161151Google Scholar
- 22.Rossi Espagnet MC, Bernardi B, Pasquini L et al (2017) Signal intensity at unenhanced T1-weighted magnetic resonance in the globus pallidus and dentate nucleus after serial administrations of a macrocyclic gadolinium-based contrast agent in children. Pediatr Radiol 47:1345–1352CrossRefGoogle Scholar
- 26.European Medicines Agency (2017) EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans: recommendations conclude EMA’s scientific review of gadolinium deposition in brain and other tissues. Report EMA/457616/2017. European Medicines Agency, LondonGoogle Scholar
- 38.Runge VM (2017) Critical questions regarding gadolinium deposition in the brain and body after injections of the gadolinium-based contrast agents, safety, and clinical recommendations in consideration of the EMA's Pharmacovigilance and Risk Assessment Committee recommendation for suspension of the marketing authorizations for 4 linear agents. Invest Radiol 52:317–323CrossRefGoogle Scholar